Abstract 95P
Background
The type of liver resection (anatomical resection, AR or nonanatomical resection, NAR) for colorectal liver metastases (CRLM) is subject to debate. The debate may persist because some certain prognostic implications, associated with worse biological behavior of tumors, have been overlooked. The aim of this study was to explore the characteristics of patients who would benefit more from the performance of AR.
Methods
475 patients who underwent hepatic resection of CRLM were included and stratified by KRAS/NRAS/BRAF mutational status. The Kaplan-Meier method was applied in relapse-free survival (RFS), and the Cox proportional hazards model was used to identify independent predictors of prognosis in multivariable analysis.
Results
Among all 475 patients, 154 (32.4%) underwent AR and 321 (67.6%) underwent NAR. 1-, 2-, and 3-year RFS for the entire cohort were 63.0%, 40.6%, and 31.2% respectively. In the cohort of patients with KRAS/NRAS/BRAF mutated tumors, patients who underwent AR had a markedly improved median RFS compared with patients who underwent NAR (24.1 VS. 12.9 months, P = 0.005). Upon the multivariable analyses, the performance of AR (hazard ratios=0.562; 95% CI 0.370-0.854, P = 0.007) remained prognostic independently for a superior RFS. In contrast, in the cohort of patients with KRAS/NRAS/BRAF wild-type tumors, patients who underwent AR had a comparable median RFS compared with those who underwent NAR (24.9 VS. 20.3 months, P = 0.901).
Conclusions
Patients with KRAS/NRAS/BRAF mutated tumors may benefit more from the performance of AR than from the performance of NAR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract